Why Is Phreesia (PHR) Stock Down -8.27% Today?
Key Takeaways
- Phreesia (PHR) shares fell about 8.27% to $10.87 after reporting mixed fiscal second-quarter results.
- The primary catalyst was an earnings miss: adjusted EPS of $0.03 came in well below the $0.09 consensus estimate.
- Revenue of roughly $129.5 million narrowly beat expectations and rose 10% year over year, but the profit shortfall overshadowed the top-line beat.
- Management maintained its fiscal 2027 revenue and adjusted EBITDA outlook, cushioning the decline but not preventing it.
- Analyst reactions were mixed, with some firms reiterating bullish ratings while Wells Fargo kept a cautious Equal Weight stance.
- Traders are now watching guidance execution, subscription revenue trends, and momentum in the company's Network Solutions segment.
Opening Summary
Phreesia, Inc. (PHR), a healthcare technology company that provides patient intake and engagement software to medical practices, saw its shares plunge in Thursday's session after a quarterly earnings miss. The stock fell approximately 8.27% to $10.87, down from a prior closing price of $11.85. The market reaction was driven by adjusted earnings that came in sharply below Wall Street expectations, even as revenue topped forecasts and the company reaffirmed its full-year outlook.
Earnings Miss Weighs on Shares
The dominant driver of the decline was Phreesia's fiscal 2027 second-quarter earnings report, released after the prior session's close. The company posted adjusted earnings per share of $0.03, missing the consensus estimate of approximately $0.09 by a wide margin. Although net income improved from the year-ago period, the magnitude of the profit shortfall relative to analyst models triggered a swift sell-off, with shares gapping down at the open.
The earnings-driven move underscores how sensitive small- and mid-cap healthcare software names can be to bottom-line results, particularly when investors have priced in a continued profitability ramp. Despite the miss, the company emphasized its fifth consecutive quarter of positive net income and its ninth consecutive quarter of positive operating and free cash flow.
Revenue Beat and Maintained Guidance Provide Partial Offset
Not all of the quarter's metrics were negative. Phreesia reported revenue of approximately $129.5 million, slightly ahead of the $129.1 million consensus and up about 10% year over year. Growth was supported by an expanding client base and momentum in the company's Network Solutions business.
Management also reaffirmed its fiscal 2027 revenue guidance of $510 million to $520 million and its adjusted EBITDA outlook of $125 million to $135 million, a move that reduced the risk of a near-term guidance cut. The company highlighted the AccessOne patient-financing acquisition as a multi-year growth opportunity and noted that it reduced debt principal by more than $23 million during the quarter, supporting an improving balance sheet. These positives helped limit losses but were not enough to offset the headline earnings miss.
Analyst Reaction Remains Mixed
The post-earnings analyst response reflected a divided view on the stock's path forward. Wells Fargo raised its price target to $10 from $9 while maintaining an Equal Weight rating, pointing to solid Network segment growth and better-than-expected adjusted EBITDA margins, but flagging continued pressure on subscription revenue. Needham reiterated a Buy rating with a $14 target, and RBC Capital maintained an Outperform rating with a $19 target, while DA Davidson reiterated a Buy at $14.
The mixed revisions signal that, while the long-term thesis around Phreesia's platform and patient-financing expansion remains intact for some analysts, near-term concerns about subscription revenue dilution and limited visibility in newer segments continue to weigh on sentiment.
Market Context and Trading Activity
Trading volume in Phreesia shares was elevated relative to recent sessions as investors repositioned following the earnings release. The stock's decline was largely company-specific rather than a reflection of broader market direction, with the move driven primarily by the earnings disappointment and a gap-down open.
The decline also brought the stock back toward key technical levels, with the share price retreating toward its 50-day moving average after recently trading above the $12 level. The gap down reflects a pronounced negative market reaction rather than a gradual drift, consistent with an earnings-driven repricing event.
What Comes Next for PHR
Investors will be closely monitoring several factors in the weeks ahead. Attention will focus on whether Phreesia can sustain its revenue growth trajectory while protecting subscription economics, given management's strategy of moderating pricing to support providers under economic strain. The company's Network Solutions segment, including the ProviderConnect pilot and its GLP-1 campaign results, will be watched as a potential growth catalyst.
Upcoming earnings, broader healthcare technology sector trends, and any further analyst rating changes could also influence the stock's direction. Risks include continued subscription revenue pressure, competitive dynamics from electronic health record vendors, and execution uncertainty around newer initiatives such as AccessOne. As always, near-term volatility around earnings should be expected.
Trending AI Robots
For investors seeking a more systematic approach to the markets, Tickeron's Trending AI Robots page highlights AI-driven trading bots that are currently performing strongly. Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in this curated section. These bots vary by strategy, timeframe, performance metrics, and traded symbols, allowing users to explore approaches that fit different investing styles. Explore the Trending AI Robots page to see which automated strategies are leading right now.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
PHR in +2.95% Uptrend, rising for three consecutive days on August 31, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where PHR advanced for three days, in of 294 cases, the price rose further within the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
Bearish Trend Analysis
The 10-day RSI Indicator for PHR moved out of overbought territory on August 14, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 61 cases where PHR's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
The Momentum Indicator moved below the 0 level on September 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PHR as a result. In of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for PHR turned negative on August 18, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PHR declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
PHR broke above its upper Bollinger Band on August 07, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. PHR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.040) is normal, around the industry mean (7.248). PHR has a moderately high P/E Ratio (74.062) as compared to the industry average of (46.219). PHR's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.545). Dividend Yield (0.000) settles around the average of (0.045) among similar stocks. P/S Ratio (1.489) is also within normal values, averaging (5.959).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PHR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 98, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of patient check-in solutions for medical practices
Industry ServicestotheHealthIndustry
Advertisement